Clinical Trial Update: The Role of SGLT2i in Management of Moderate AS [Phase 2, Phase 3]

View source ↗

Summary

Ongoing Phase 2 and Phase 3 study, sponsored by the University of East Anglia, evaluating SGLT2 inhibitors for moderate aortic valve stenosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Valve Stenosis

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: University of East Anglia | Conditions: Moderate Aortic Valve Stenosis | Phase 2, Phase 3 | Status: RECRUITING